Skip to content
今天3分钟我们来聊聊干细胞治疗阿尔茨海默病10例:联合方案疗效优于单一路径 episode artwork

EPISODE · Jul 10, 2026 · 5 MIN

今天3分钟我们来聊聊干细胞治疗阿尔茨海默病10例:联合方案疗效优于单一路径

from 源于细胞BioInsid的个人播客

中国阿尔茨海默病患者近1700万,现有药物无法治愈。一项早期本土研究显示,干细胞原位治疗与自体骨髓干细胞移植联合应用,可改善患者认知和生活能力,且安全性良好,为AD治疗提供新方向。 信息来源: 中华网山东频道:《山东省脐血库参与!全国首个脐血NK治疗儿童肿瘤项目完成备案》,2026年6月9日 OncoImmunology论文:Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human. DOI: 10.1080/2162402X.2026.2679315 备案号:MR-N-44-2026-000004 项目名称:一项脐带血自然杀伤(NK)细胞治疗高危、复发/难治性神经母细胞瘤的I期临床研究 参与机构:中山大学肿瘤防治中心儿童肿瘤科(张翼鷟团队)、山东省脐血库、山东省齐鲁干细胞工程有限公司 前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Jul 10, 2026

Embed this episode

Ready to play

今天3分钟我们来聊聊干细胞治疗阿尔茨海默病10例:联合方案疗效优于单一路径

0:00 5:58

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 源于细胞BioInsid的个人播客?

This episode is 5 minutes long.

When was this 源于细胞BioInsid的个人播客 episode published?

This episode was published on July 10, 2026.

Can I download this 源于细胞BioInsid的个人播客 episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!